Quince Therapeutics (QNCX) Liabilities and Shareholders Equity (2018 - 2026)

Quince Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $26.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 75.14% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $347.3 million (down 28.09% YoY), while the FY2025 annual figure was $93.5 million, down 18.3% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $26.6 million, down from $93.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $167.9 million in Q4 2023, with the low at $26.6 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $109.9 million (2025), against an average of $110.2 million.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity jumped 70.7% in 2024, then tumbled 75.14% in 2026.
• Quince Therapeutics' Liabilities and Shareholders Equity stood at $103.9 million in 2022, then soared by 61.58% to $167.9 million in 2023, then sank by 31.82% to $114.5 million in 2024, then retreated by 18.3% to $93.5 million in 2025, then plunged by 71.53% to $26.6 million in 2026.
• Business Quant data shows QNCX's Liabilities and Shareholders Equity at $26.6 million in Q1 2026, $93.5 million in Q4 2025, and $109.9 million in Q3 2025.